Your browser doesn't support javascript.
loading
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.
Hütter-Krönke, Marie Luise; Fiedler, Walter; Kündgen, Andrea; Krauter, Jürgen; von Lilienfeld-Toal, Marie; Döhner, Hartmut; Schlenk, Richard F.
Affiliation
  • Hütter-Krönke ML; Department of Internal Medicine III, University of Ulm marie-luise.huetter@uniklinik-ulm.de.
  • Fiedler W; Department of Internal Medicine II, University Hospital Hamburg-Eppendorf, Hamburg.
  • Kündgen A; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University Düsseldorf.
  • Krauter J; Department of Internal Medicine III, Hospital Braunschweig.
  • von Lilienfeld-Toal M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany.
  • Döhner H; Department of Internal Medicine II, University Hospital Jena.
  • Schlenk RF; Department of Internal Medicine III, University of Ulm.
Haematologica ; 104(2): e63-e64, 2019 02.
Article in En | MEDLINE | ID: mdl-30171028
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Lenalidomide / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies Limits: Humans Language: En Journal: Haematologica Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Lenalidomide / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies Limits: Humans Language: En Journal: Haematologica Year: 2019 Document type: Article